政大機構典藏-National Chengchi University Institutional Repository(NCCUR):Item 140.119/106995

政大機構典藏-National Chengchi University Institutional Repository(NCCUR):Item 140.119/106995

English | 正體中文 | 简体中文 | Post-Print筆數 : 27 | 全文笔数/总笔数 : 113393/144380 (79%)
造访人次 : 51238768 在线人数 : 870

RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.

搜寻范围

查询小技巧：

您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果

若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据

进阶搜寻

主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于政大典藏 ‧ 管理

到手机版

政大機構典藏 > 商學院 > 科技管理與智慧財產研究所 > 學位論文 > Item 140.119/106995

请使用永久网址来引用或连结此文件: https://nccur.lib.nccu.edu.tw/handle/140.119/106995

题名:	生技製藥企業之智財併購策略－以輝瑞藥廠為例 The M&A strategy of intellectual property management in bio-pharmaceutical industry - a case study of Pfizer Inc.
作者:	翁以哲 Weng, Yi Che
贡献者:	馮震宇 Feng, Chen Yu 翁以哲 Weng, Yi Che
关键词:	企業併購策略管理新藥開發智財併購策略 Mergers and Acquisitions Stratgic Management New Drug Development M&A Strategy of Intellectual Property Rights Management
日期:	2017
上传时间:	2017-03-01 17:35:57 (UTC+8)
摘要:	近幾年生技製藥企業的跨國併購活動頻繁，動輒數百億美元的鉅額交易案不時出現在各大媒體版面，風起雲湧的併購活動顯示出併購乃生技製藥產業獲取高價值技術資源的重要策略之ㄧ。而現今藥廠面臨的挑戰包括：研發費用增加幅度高於銷售成長、新藥開發速度較產業需求緩慢、必須從其他生技新藥企業獲取授權產品與技術，及面臨許多藥品將喪失專利權、虎視眈眈的學名藥廠的威脅。生技製藥產業的發展有漸趨集中化的趨勢，全球前十大藥廠的銷售額約佔總藥品市場的一半，在全球醫療環境改變、人口老化、新興治療模式等需求下，又面臨全球醫療保險給付、專利藥品過期的威脅，藥廠併購擁有創新技術與不同類型產品的生技公司勢必不會消退。藥品研發期長、高產品開發風險使得小型生技新藥企業常面臨資金短缺的問題，而大藥廠豐沛的資金、擅長開發、製造、市場及行銷的特性，促使藥業與生技業併購風潮四起。本研究即以生技製藥產業內的龍頭Pfizer為研究主體，探討大型藥廠的併購動機，與其以獲取智慧財產權為目的的併購策略的規劃。藉由本論文對個案公司背景、併購歷程、併購策略、產品組合、研發與智財等面向的探討，期望能提供台灣生技新藥企業尋求成長時的參考，是否除了透過IPO上市取得資金外，也能透過併購或被收購來加速發展，使台灣生技的研發製造能量提升到國際舞台上。 Tens of billions of dollars in large transactions shows that M&As are one of the most important strategies for pharmaceutical and the biotechnology industry to gain access to valuable technological resources in recent years. Nowadays, the challenges of pharmaceutical company include the growth rate of R&D cost were higher than sales, new drugs development were slower than industry demand, licensing from other company and high profit patent drugs turned into generics, which facing the threat from other competitors. The development of pharmaceutical company becoming more concentrated that the top ten pharmaceutics account for half of the global sales. Moreover, with the growing demand from the health care, aging and novel therapeutics and under the threatens of health insurance payment and patent cliff, the tide of M&As for pharmaceutical and biotech companies will not decline. The purpose of M&A activities from the global top pharmaceutical companies, is to obtaining innovative technology and different types of biotechnology company. However, large R&D expenditure and high risk product development result in capital shortage problems. The abundant working capital and well-experienced manufacture, marketing and sales characteristics of big pharma enable the M&As of pharma and biotech arise. The M&A strategic planning of acquiring intellectual property rights of the leading pharmaceutical company was investigated in this study. The background of Pfizer, its M&A process, strategies, product matrix, R&D and intellectual property-oriented discussion were examined. Therefore, this study may fulfill and provide some suggestions and references for further pharmaceutical and biotech M&A activities in Taiwanese biotechnology companies such as JHL. Except for seeking IPO as the only growing strategy, through M&A is another way to accelerate the development of Taiwan`s biotechnology R&D and manufacturing ability to the international level.
參考文獻:	中文文獻專書、學位論文、研究報告張勝春，2006，企業併購法制之經濟分析，第四章麥可波特, 2009, 競爭論, 天下文化出版社森秀明, 2015, 外商顧問超強資料製作術, 時報出版社游明德等, 2016, 企業併購策略與最佳實務(第三版), 三民出版社台灣併購與私募股權協會，2016，企業併購的第一堂課，洪圖出版社，CH2 謝昀成，2014，公開收購法制與爭議問題之研究-以英美及我國法制為中心羅敏菁，2011，生技投資聖經-看懂台灣生技股的第一本書，旗標出版社，CH3 經濟部生技醫藥產業發展推動小組，2016，2016生技產業白皮書，CH2, 3 《金融家月刊》第63期，2013 崔聖如，2014，式微的巨人，Pfizer下一步該怎麼走，工研院撥開迷霧看生技：生技，原來要這樣看，2016，聯經出版社，p. 49-51 彭劍鋒，2016，輝瑞-造就全球第一健康守護者，有意思出版社，CH2,3 周延鵬，2015，智富密碼：智慧財產運贏及貨幣化，CH8 Dennis J.Roberts, 2014, 并购之王：投行老狐狸深度披露企业并购内幕, 金多多出版社, CH3 陳則銘，2003，企業併購之相關智慧財產管理策略與法律規劃研究－以併購美國高科技公司時之專利查核評估探微網路資料美國專利訴訟史上最高侵權賠償25.4億美元：Idenix Pharmaceuticals，科技產業資訊室，http://iknow.stpi.narl.org.tw/Post/Read.aspx?PostID=13056 台灣併購與私募股權協會，http://www.mapect.com/knowledge_organ_pra01.php 葉雲卿，淺談美國專利聯結制度系列，北美智權報123-125期，http://www.naipo.com/Portals/1/web_tw/Knowledge_Center/Industry_Economy/publish-318.htm Money DJ理財網，簡易新藥申請規定（Abbreviated New Drug Application），http://www.moneydj.com/KMDJ/wiki/wikiViewer.aspx?keyid=b2d09132-82ef-4553-9264-de3a3bf00513 林孝樺，藥廠業務重組的選擇-併購或資產交換，http://www.phycos.com.tw/articles/109 這10家生物醫藥公司是華爾街下一個併購的「香餑餑」，2016，壹讀， https://read01.com/KGgyDB.html Deloitte 新藥研發模式白皮書 2016，https://www2.deloitte.com/tw/tc/pages/life-sciences-and-healthcare/articles/2016drug-development.html 英文文獻專書、學位論文、研究報告 Deloitte Insights, 2016, Measuring the return from pharmaceutical innovation 2015 DIENS, L. R., 2002, Maximising the value of intellectual property assets in US M&A, Tax planning international M&A, Vol.1, No.3,3-7 Michael A.Hitt,R. Duane Ireland,Robert E.Hoskisson ,1999, Strategic Management 3rd edition,p 216,240,245. Aiswariya Chidambaram ,et al., 2014, Generic Pharmaceuticals Market–A Global Analysis Ripe for Growth and Opportunities：Several Key Blockbuster Drugs to go off Patent Jonathan Norris, 2014, Trends in Healthcare Investments and Exits Jayne Pearl , 2001, Value of investments in intangibles, MIT Sloan Management Review 2001 , p13-14 Turowski, D.,2011,Intellectual Property: its growing to corporate finance, in WILD, J., op. cit., p.9 Bruce Berman,2002,From Idea to Assets: Investing Wisely in Intellectual Property, New York: John Wiley & Sons, Inc., p.281-282 Pfizer 2010-2016 Financial Report 網路資料 2016 Global Innovation 1000 Study, http://www.strategyand.pwc.com/innovation1000#GlobalKeyFindingsTabs4\|VisualTabs3
描述:	碩士國立政治大學科技管理與智慧財產研究所 103364209
資料來源:	http://thesis.lib.nccu.edu.tw/record/#G0103364209
数据类型:	thesis
显示于类别:	[科技管理與智慧財產研究所] 學位論文

文件中的档案:

档案	描述	大小	格式	浏览次数
420901.pdf		4987Kb	Adobe PDF2	319	检视/开启

在政大典藏中所有的数据项都受到原著作权保护.

社群 sharing

著作權政策宣告 Copyright Announcement

1.本網站之數位內容為國立政治大學所收錄之機構典藏，無償提供學術研究與公眾教育等公益性使用，惟仍請適度，合理使用本網站之內容，以尊重著作權人之權益。商業上之利用，則請先取得著作權人之授權。
The digital content of this website is part of National Chengchi University Institutional Repository. It provides free access to academic research and public education for non-commercial use. Please utilize it in a proper and reasonable manner and respect the rights of copyright owners. For commercial use, please obtain authorization from the copyright owner in advance.

2.本網站之製作，已盡力防止侵害著作權人之權益，如仍發現本網站之數位內容有侵害著作權人權益情事者，請權利人通知本網站維護人員(nccur@nccu.edu.tw)，維護人員將立即採取移除該數位著作等補救措施。
NCCU Institutional Repository is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff(nccur@nccu.edu.tw). We will remove the work from the repository and investigate your claim.

DSpace Software Copyright © 2002-2004 MIT & Hewlett-Packard / Enhanced by NTU Library IR team Copyright © - 回馈